NasdaqCM - Nasdaq Real Time Price • USD
ARCA biopharma, Inc. (ABIO)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 4:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2020) | Next Qtr. (Dec 2020) | Current Year (2020) | Next Year (2021) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.76 | -0.77 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2020) | Next Qtr. (Dec 2020) | Current Year (2020) | Next Year (2021) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2019 | 12/31/2019 | 3/31/2020 | 6/30/2020 |
|---|---|---|---|---|
| EPS Est. | -1.3 | -0.99 | -2.04 | -2.58 |
| EPS Actual | -0.76 | -0.77 | -0.83 | -0.73 |
| Difference | 0.54 | 0.22 | 1.21 | 1.85 |
| Surprise % | 41.50% | 22.20% | 59.30% | 71.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2020) | Next Qtr. (Dec 2020) | Current Year (2020) | Next Year (2021) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -2.51 | -2.44 | -9.59 | -8.8 |
| 30 Days Ago | -2.51 | -2.44 | -9.59 | -8.8 |
| 60 Days Ago | -2.51 | -2.44 | -9.59 | -8.8 |
| 90 Days Ago | -2.51 | -2.44 | -9.59 | -8.8 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2020) | Next Qtr. (Dec 2020) | Current Year (2020) | Next Year (2021) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ABIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | Dawson James: Buy | 10/9/2013 |
Related Tickers
ELYM Eliem Therapeutics, Inc.
4.1800
-5.64%
SNGX Soligenix, Inc.
0.4353
-14.65%
ACRV Acrivon Therapeutics, Inc.
10.54
+1.93%
XLO Xilio Therapeutics, Inc.
1.2800
+4.07%
PXMD PaxMedica, Inc.
0.7631
-4.60%
ALLR Allarity Therapeutics, Inc.
1.5400
+2.67%
RLYB Rallybio Corporation
1.6700
-5.11%
EYEN Eyenovia, Inc.
0.5309
-1.56%
ONVO Organovo Holdings, Inc.
1.1500
+2.68%
CADL Candel Therapeutics, Inc.
5.46
+0.37%